

This material was developed by Dr. Reddy's Laboratories, as part of the risk minimization plan for Reddy-Lenalidomide and Reddy-Pomalidomide. This material is not intended for promotional use.

Keep a copy of this survey for your records.

Reddy-Lenalidomide RMP Program and Reddy-Pomalidomide RMP Program: PRESCRIBER SURVEY

Prescriber ID:

Patient ID:

Name of the treatment:

To make these Risk Management Educational Programs more effective, Dr. Reddy's Laboratories Canada Inc. is conducting this survey and your participation is requested:

- i) Have you counseled your patient on the teratogenic effects of their respective treatment (Reddy-Lenalidomide or Reddy-Pomalidomide)?
 - a) Yes
 - b) No

 - ii) If this is the initial prescription, have you administered two serum pregnancy tests prior to writing the prescription?
 - a) Yes
 - b) No
 - c) Not Applicable

 - iii) Were the results of the pregnancy tests negative?
 - a. Yes
 - b. No

 - iv) What was the date of the patient's last negative pregnancy test?

 - v) At the time of their initial visit, do you offer your patients a detailed discussion of educational material so that they understand the serious side effects?
 - a) Yes
 - b) No
 - c) I prefer not to answer

 - vi) At the time of prescribing Reddy-Lenalidomide or Reddy-Pomalidomide, what teratogenic side effects in particular should you warn your patients about
 - a) Fetal abnormalities
 - b) Spontaneous abortion
 - c) Both of the above
 - d) None of the above

 - vii) Prescriptions of Reddy-Lenalidomide or Reddy-Pomalidomide for women of childbearing potential must be:
 - a) Limited to 30 days of treatment
 - b) Limited to 45 days of treatment
 - c) No limitation throughout the course after one negative pregnancy test
 - d) Dispensed within 7 days of the medically supervised negative pregnancy test
 - e) a & d
 - f) c & d
-

For more information about Reddy-Lenalidomide and Reddy-Pomalidomide, and their respective Risk Management programs, please visit www.reddy2assist.com or call for assistance at 1-877-938-0670.

Return this form completed to Dr. Reddy's Laboratories Canada Inc. via email, fax or mail:

Rx Infinity, Attn: Reddy2Assist Program

5155 Spectrum Way, Unit 29,

Mississauga ON L4W 5A1

Phone: 1-877-938-0670

Fax: 1-877-938-0807

Email: reddy2assist@drreddys.com

Website: www.reddy2assist.com

Keep a copy of this survey for your records.

Confidentiality Statement

The information in this document is confidential and the property of Dr. Reddy's Laboratories Canada Inc. No part of it may be transmitted, reproduced, published or used by any person/s without prior written authorisation from Dr. Reddy's Laboratories Canada Inc.

This Reddy-Lenalidomide RMP Program and Reddy-Pomalidomide RMP Program: PRESCRIBER SURVEY is downloaded from www.reddy2assist.com, where more information about Reddy-Lenalidomide (lenalidomide), and Reddy-Pomalidomide (pomalidomide) and their respective Risk Management Programs can be found.
